Search

everythinglearnresearchcommunity

for

Search:↓

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.

The conversation is about the results of using hormone replacement therapy (HRT) with estrogen and finasteride for hair loss, and switching from finasteride to bicalutamide as an anti-androgen treatment. The user shared before and after photos to discuss the effectiveness of these treatments.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Biotin supplements are not effective for hair loss unless you are actually deficient, which is rare. Some users report improved hair quality with biotin, but there's no evidence supporting its use for hair loss in healthy individuals.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

User regrew lost hair using microneedling, minoxidil, finasteride, Nizoral, fish oil, and collagen peptide. Progress was slow but constant, and patience was important.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

Hair loss discussion includes DIY HMI-115 and its high cost (20-30k per person). Minoxidil, finasteride, and RU58841 mentioned as treatments.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.